Key Points
- CEO Simeon Kohl bought 59,000 Health Catalyst shares at an average price of $1.79, investing $105,610 and increasing his ownership by 2.11% to 2.86 million shares.
- Health Catalyst reported quarterly revenue of $70.49 million and EPS of $0.04, beating analyst estimates, but remains unprofitable with a negative net margin of 90.61%; analysts expect a full-year loss.
- Analyst sentiment remains cautious, with a consensus “Hold” rating and an average price target of $2.45 after several firms reduced their targets. Institutional investors own approximately 85% of the company.
Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) CEO Simeon Kohl acquired 59,000 shares of the business's stock in a transaction dated Monday, September 14th. The stock was acquired at an average cost of $1.79 per share, for a total transaction of $105,610.00. Following the transaction, the chief executive officer owned 2,856,385 shares of the company's stock, valued at $5,112,929.15. This represents a 2.11% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Health Catalyst Stock Performance
Shares of HCAT opened at $1.73 on Thursday. Health Catalyst, Inc. has a 12 month low of $0.96 and a 12 month high of $3.62. The firm has a fifty day simple moving average of $1.90 and a 200 day simple moving average of $1.64. The stock has a market capitalization of $130.20 million, a price-to-earnings ratio of -0.47 and a beta of 1.53. The company has a current ratio of 2.70, a quick ratio of 2.70 and a debt-to-equity ratio of 1.51.
Health Catalyst (NASDAQ:HCAT - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.01. The firm had revenue of $70.49 million for the quarter, compared to analyst estimates of $69.09 million. Health Catalyst had a negative net margin of 90.61% and a negative return on equity of 1.83%. Research analysts forecast that Health Catalyst, Inc. will post -0.18 EPS for the current fiscal year.
Analysts Set New Price Targets
A number of brokerages have recently issued reports on HCAT. Weiss Ratings upgraded Health Catalyst from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Tuesday, July 28th. Citigroup lowered their target price on shares of Health Catalyst from $2.50 to $2.00 and set a "neutral" rating on the stock in a report on Tuesday, August 11th. Canaccord Genuity Group reissued a "hold" rating and issued a $1.80 price objective (down from $3.00) on shares of Health Catalyst in a research report on Thursday, August 20th. Finally, Wells Fargo & Company lowered their price objective on shares of Health Catalyst from $1.75 to $1.50 and set an "equal weight" rating on the stock in a research note on Thursday, August 13th. Three research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $2.45.
Read Our Latest Stock Analysis on HCAT
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the business. Visionary Wealth Advisors bought a new position in shares of Health Catalyst during the second quarter valued at $27,000. Hsbc Holdings PLC grew its holdings in Health Catalyst by 21.3% during the 1st quarter. Hsbc Holdings PLC now owns 98,868 shares of the company's stock worth $123,000 after acquiring an additional 17,332 shares during the period. Whetstone Capital Advisors LLC grew its holdings in Health Catalyst by 0.5% during the 4th quarter. Whetstone Capital Advisors LLC now owns 3,750,377 shares of the company's stock worth $8,963,000 after acquiring an additional 19,027 shares during the period. AXQ Capital LP bought a new position in shares of Health Catalyst in the 2nd quarter worth about $38,000. Finally, Williams & Novak LLC raised its position in shares of Health Catalyst by 56.9% in the 2nd quarter. Williams & Novak LLC now owns 53,607 shares of the company's stock worth $107,000 after acquiring an additional 19,442 shares in the last quarter. 85.00% of the stock is currently owned by institutional investors.
Health Catalyst Company Profile
(
Get Free Report)
Health Catalyst, Inc is a healthcare technology and data analytics company that helps healthcare organizations use data to improve clinical outcomes, operational performance and financial results. The company provides software, data management capabilities and professional services designed to support hospitals, health systems, medical groups and other healthcare providers.
Its offerings include the Health Catalyst Data Operating System, which integrates and organizes data from disparate clinical, financial and operational systems, as well as analytics applications for areas such as quality improvement, population health, cost management and care delivery.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
